No long-term effect of behavioral treatment on psychotropic drug use for agitation in Alzheimer's disease patients

J Geriatr Psychiatry Neurol. 2002 Summer;15(2):95-8. doi: 10.1177/089198870201500208.

Abstract

Th determine if teaching caregivers behavior management techniques (BMTs) reduces long-term psychotropic use in Alzheimer's disease (AD) patients, we examined 12-month follow-up data from a 4-month randomized study comparing placebo, BMTs, trazodone, and haloperidol for the treatment of agitated behaviors in persons with AD. After 4 months, treatment was allowed with any agent. Between 42.8% and 51% of AD patients received additional psychotropics between 4 and 12 months. The relative risk of being prescribed any psychotropic drug after the 4-month trial was at or about 1.0 for subjects in each drug arm or placebo arm versus BMTs. We concluded that teaching caregivers BMTs did not diminish long-term prescription of psychotropic drugs.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / psychology*
  • Anti-Anxiety Agents / therapeutic use
  • Antipsychotic Agents / therapeutic use*
  • Behavior Therapy*
  • Caregivers / psychology
  • Female
  • Follow-Up Studies
  • Haloperidol / therapeutic use
  • Humans
  • Interviews as Topic
  • Male
  • Psychiatric Status Rating Scales
  • Psychomotor Agitation / drug therapy*
  • Psychomotor Agitation / psychology*
  • Psychotropic Drugs / therapeutic use*
  • Time Factors
  • Trazodone / therapeutic use

Substances

  • Anti-Anxiety Agents
  • Antipsychotic Agents
  • Psychotropic Drugs
  • Haloperidol
  • Trazodone